In a message dated 03/04/98 11:10:04 GMT, Mark Campbell wrote:
<< But these savings may be substantial and sufficient to allow us to
stay within allocation, fund new treatments or both.
Current annual potential savings from increased generic
prescribing are probably in excess of UKP 15 M for England. Also,
generic prescribing is not a short term fix
either. The savings are recurrent with each patent expiry. >>
Our practice has never espoused generic prescribing. Our current rate is
about 29%
. We have a high elderly population and a lot of hypertensvice patients and
those with IHD. 50% of our ptatients with LVF are on ACE as are many of our
hypertensives. Our |CVS spend is 54% above average and our Resp spend about
35% above average. Overall we are 3.9% below budget and our moving average
growth rate is well below average both nationally and for Dorset.
Its all done by discriminating prescribing. No mirrors involved.
Michael Blackmore , West Moors, Dorset
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|